You are here

Article Text

Article menu
Download PDFPDF
Treatment
Oestrogen plus progestin increased coronary heart disease and breast cancer in postmenopausal women

https://doi.org/10.1136/ebn.6.1.20

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Writing Group for the Women’s Health Initiative Investigators.Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial.JAMA2002 ;288:321–33OpenUrlCrossRefPubMedWeb of Science

    QUESTION: In postmenopausal women, what are the risks and benefits of oestrogen plus progestin use, particularly with respect to coronary heart disease (CHD) events?

    Design

    Randomised (allocation concealed), blinded (clinicians, participants, data collectors, outcome assessors, and monitoring committee), placebo controlled trial with a mean 5.2 years of follow up.

    Setting

    40 US clinical centres.

    Patients

    16 608 postmenopausal women who were 50–79 years of age (mean age 63.3 y) with an intact uterus at baseline. Exclusion criteria included medical conditions associated with probable survival of <3 years, previous breast cancer or other cancer in the past 10 years (except non-melanoma skin cancer), low hematocrit or …

    View Full Text

    Footnotes

    • For correspondence: Dr J E Rossouw, Division of Women’s Health Initiative, National Heart, Lung, and Blood Institute, Bethesda, MD, USA. rossouw{at}nih.gov

    • A modified version of this abstract appears in ACP Journal Club and Evidence-Based Medicine.

    • Sources of funding: National Heart, Lung and Blood Institute and Wyeth-Ayerst Research.